Figures 2C, D indicate that when compared to the CTL group, the DOX group’s BUN and Bcr levels increased 153% and 85%, respectively. GL-PP treatment led to a notable decrease in BUN levels by 43% and Bcr levels by 28% compared to the DOX group. Additionally, after DOX treatment, TG levels increased by 2.05×; however, GL-PP reversed DOX-induced hyperlipidemia, resulting in 72% reductions in TG levels (Figure 2E). This evidence concerns the gene BCR and hyperlipidemia.